Published in J Bone Miner Res on March 01, 2012
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol (2013) 1.40
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int (2015) 1.29
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int (2012) 1.29
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging (2012) 0.98
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97
The Brady Bunch? New evidence for nominative determinism in patients' health: retrospective, population based cohort study. BMJ (2013) 0.96
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int (2013) 0.95
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc (2016) 0.95
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int (2015) 0.95
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J (2012) 0.92
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence (2014) 0.86
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Osteonecrosis of the jaw in patient with denosumab therapy. Int J Clin Exp Med (2014) 0.83
Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab (2014) 0.83
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int (2014) 0.83
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2015) 0.81
Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. Rheumatol Int (2013) 0.81
Observations following discontinuation of long-term denosumab therapy. Osteoporos Int (2017) 0.81
Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent (2016) 0.80
Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging (2014) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int (2015) 0.79
New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med (2015) 0.79
Osteochemonecrosis: an overview. Head Neck Pathol (2014) 0.79
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int (2015) 0.78
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag (2016) 0.77
Interaction between bone and muscle in older persons with mobility limitations. Curr Pharm Des (2014) 0.77
Update on denosumab in postmenopausal osteoporosis--recent clinical data. Wien Med Wochenschr (2012) 0.76
Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review. Clin Cases Miner Bone Metab (2016) 0.76
How long should we treat? Osteoporos Int (2014) 0.75
The Prevention of Medication-related Osteonecrosis of the Jaw. Dtsch Arztebl Int (2017) 0.75
Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J (2017) 0.75
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis. J Osteoporos (2016) 0.75
Update on denosumab treatment in postmenopausal women with osteoporosis. Endocrinol Metab (Seoul) (2015) 0.75
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskelet Disord (2017) 0.75
Denosumab 5-year data in postmenopausal women with osteoporosis. Bonekey Rep (2012) 0.75
Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension. Yonsei Med J (2016) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Small sample inference for fixed effects from restricted maximum likelihood. Biometrics (1997) 16.06
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res (1993) 10.98
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol (2005) 2.03
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med (2010) 1.14
Placebo-controlled trials in osteoporosis--proceeding with caution. N Engl J Med (2010) 1.11
Safety of denosumab in giant-cell tumour of bone. Lancet Oncol (2010) 1.07
The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med (2010) 1.01
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA (2008) 6.50
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med (2002) 5.42
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol (2003) 4.28
Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry (2010) 4.27
LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell (2004) 4.20
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol (2004) 4.03
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med (2006) 3.93
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol (2008) 3.68
Frequency of stress testing to document ischemia prior to elective percutaneous coronary intervention. JAMA (2008) 3.62
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health (2005) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Support from hospital to home for elders: a randomized trial. Ann Intern Med (2014) 3.21
Recommendations for intrauterine contraception: a randomized trial of the effects of patients' race/ethnicity and socioeconomic status. Am J Obstet Gynecol (2010) 3.18
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Modelling clustered survival data from multicentre clinical trials. Stat Med (2004) 3.02
Food insecurity is associated with diabetes mellitus: results from the National Health Examination and Nutrition Examination Survey (NHANES) 1999-2002. J Gen Intern Med (2007) 3.01
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet (2002) 3.00
Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity (2009) 2.99
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA (2002) 2.91
Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg (2009) 2.89
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med (2004) 2.86
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Effect of awareness of language law on language access in the health care setting. J Gen Intern Med (2006) 2.82
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res (2008) 2.66
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62